These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 18261916

  • 1. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V, López-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J.
    Cancer; 1996 Aug 15; 78(4):736-40. PubMed ID: 8756365
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ, De Miguel J, García Díaz JD, Díez M.
    Anticancer Res; 2008 Aug 15; 28(5B):2947-52. PubMed ID: 19031938
    [Abstract] [Full Text] [Related]

  • 4. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar 15; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 5. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
    Sthaneshwar P, Yap SF, Jayaram G.
    Malays J Pathol; 2002 Jun 15; 24(1):53-8. PubMed ID: 16329556
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr 15; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 7. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A, Lynne LC, Howell L.
    Diagn Cytopathol; 2007 Feb 15; 35(2):105-10. PubMed ID: 17230576
    [Abstract] [Full Text] [Related]

  • 8. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Feb 15; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 9. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Feb 15; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 10. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar 15; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
    Kuralay F, Tokgöz Z, Cömlekci A.
    Clin Chim Acta; 2000 Oct 15; 300(1-2):43-55. PubMed ID: 10958862
    [Abstract] [Full Text] [Related]

  • 13. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD, Ewald N.
    Expert Rev Mol Diagn; 2008 Sep 15; 8(5):579-85. PubMed ID: 18785806
    [Abstract] [Full Text] [Related]

  • 14. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, Mischinger HJ.
    Anticancer Res; 1999 Sep 15; 19(1B):849-51. PubMed ID: 10216504
    [Abstract] [Full Text] [Related]

  • 15. [Diagnostic efficiency of serum lipid-bound sialic acid level in malignant pleural effusions].
    Bektemür G, Ozer F, Kanat F, Imecik O.
    Tuberk Toraks; 2003 Sep 15; 51(3):265-70. PubMed ID: 15143404
    [Abstract] [Full Text] [Related]

  • 16. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H, Rona G, Hutter C, Bayer PM, Kummer F.
    Wien Klin Wochenschr; 1986 Sep 12; 98(17):564-73. PubMed ID: 3020811
    [Abstract] [Full Text] [Related]

  • 17. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J, Schulze G.
    Anticancer Res; 2003 Sep 12; 23(6D):5089-93. PubMed ID: 14981971
    [Abstract] [Full Text] [Related]

  • 18. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
    Li CS, Cheng BC, Ge W, Gao JF.
    Int J Clin Pract; 2007 Mar 12; 61(3):444-8. PubMed ID: 17313612
    [Abstract] [Full Text] [Related]

  • 19. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999 Mar 12; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 20. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J, Bitterlich N, Schulze G.
    Anticancer Res; 2005 Mar 12; 25(3A):1507-15. PubMed ID: 16033052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.